DE69006684T2 - Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit. - Google Patents
Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit.Info
- Publication number
- DE69006684T2 DE69006684T2 DE69006684T DE69006684T DE69006684T2 DE 69006684 T2 DE69006684 T2 DE 69006684T2 DE 69006684 T DE69006684 T DE 69006684T DE 69006684 T DE69006684 T DE 69006684T DE 69006684 T2 DE69006684 T2 DE 69006684T2
- Authority
- DE
- Germany
- Prior art keywords
- per dose
- combination
- acetaminophen
- cimetidine
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Revoked
Links
- 239000000203 mixture Substances 0.000 title claims description 30
- 239000003814 drug Substances 0.000 title claims description 26
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 208000024891 symptom Diseases 0.000 title abstract description 22
- 238000011282 treatment Methods 0.000 title description 10
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims abstract description 49
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract description 22
- 229960005489 paracetamol Drugs 0.000 claims abstract description 20
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract description 19
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims abstract description 13
- 210000004211 gastric acid Anatomy 0.000 claims abstract description 11
- 229940126409 proton pump inhibitor Drugs 0.000 claims abstract description 11
- 239000000612 proton pump inhibitor Substances 0.000 claims abstract description 11
- 239000003485 histamine H2 receptor antagonist Substances 0.000 claims abstract description 8
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 8
- 239000000938 histamine H1 antagonist Substances 0.000 claims abstract description 7
- 229940079593 drug Drugs 0.000 claims description 19
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 17
- 229960000520 diphenhydramine Drugs 0.000 claims description 17
- 229960001680 ibuprofen Drugs 0.000 claims description 17
- 229960001380 cimetidine Drugs 0.000 claims description 13
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 claims description 13
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 12
- 229960000620 ranitidine Drugs 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 11
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims description 9
- 229960000381 omeprazole Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 8
- 230000000903 blocking effect Effects 0.000 claims description 6
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 claims description 5
- 108090000110 Histamine H1 Receptors Proteins 0.000 claims description 5
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 5
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 claims description 5
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 5
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 claims description 5
- UVKZSORBKUEBAZ-UHFFFAOYSA-N cyclizine Chemical compound C1CN(C)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 UVKZSORBKUEBAZ-UHFFFAOYSA-N 0.000 claims description 5
- 229960003564 cyclizine Drugs 0.000 claims description 5
- 229960001419 fenoprofen Drugs 0.000 claims description 5
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 claims description 5
- 229960000930 hydroxyzine Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 5
- 229960000991 ketoprofen Drugs 0.000 claims description 5
- 229940013798 meclofenamate Drugs 0.000 claims description 5
- 229960002009 naproxen Drugs 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- 229960002702 piroxicam Drugs 0.000 claims description 5
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 5
- 229960003910 promethazine Drugs 0.000 claims description 5
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims description 5
- 229960000894 sulindac Drugs 0.000 claims description 5
- 229960001017 tolmetin Drugs 0.000 claims description 5
- UPSPUYADGBWSHF-UHFFFAOYSA-N tolmetin Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC=C(CC(O)=O)N1C UPSPUYADGBWSHF-UHFFFAOYSA-N 0.000 claims description 5
- 229960003223 tripelennamine Drugs 0.000 claims description 5
- 102000003834 Histamine H1 Receptors Human genes 0.000 claims description 4
- OCJYIGYOJCODJL-UHFFFAOYSA-N Meclizine Chemical compound CC1=CC=CC(CN2CCN(CC2)C(C=2C=CC=CC=2)C=2C=CC(Cl)=CC=2)=C1 OCJYIGYOJCODJL-UHFFFAOYSA-N 0.000 claims description 4
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 claims description 4
- 229960000428 carbinoxamine Drugs 0.000 claims description 4
- 229960003291 chlorphenamine Drugs 0.000 claims description 4
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 4
- 229960004993 dimenhydrinate Drugs 0.000 claims description 4
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 claims description 4
- 229960001474 meclozine Drugs 0.000 claims description 4
- 229960003464 mefenamic acid Drugs 0.000 claims description 4
- 229960000582 mepyramine Drugs 0.000 claims description 4
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 claims description 4
- 239000007894 caplet Substances 0.000 claims description 3
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001596 famotidine Drugs 0.000 claims description 3
- 150000005599 propionic acid derivatives Chemical class 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 4
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims 2
- 239000003617 indole-3-acetic acid Substances 0.000 claims 1
- 239000007935 oral tablet Substances 0.000 claims 1
- 229940096978 oral tablet Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 25
- 201000006549 dyspepsia Diseases 0.000 description 23
- 235000019441 ethanol Nutrition 0.000 description 19
- 239000003826 tablet Substances 0.000 description 17
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 14
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 14
- 229960001138 acetylsalicylic acid Drugs 0.000 description 14
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 13
- 239000000975 dye Substances 0.000 description 13
- 208000024798 heartburn Diseases 0.000 description 12
- 206010019233 Headaches Diseases 0.000 description 10
- 208000029618 autoimmune pulmonary alveolar proteinosis Diseases 0.000 description 10
- 231100000869 headache Toxicity 0.000 description 10
- 108010002059 Histamine Receptors Proteins 0.000 description 7
- 102000000543 Histamine Receptors Human genes 0.000 description 7
- 229960001340 histamine Drugs 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 210000001156 gastric mucosa Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 206010000059 abdominal discomfort Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 101150056637 Hrh2 gene Proteins 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 208000024981 pyrosis Diseases 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- -1 Aliphatic Alcohols Chemical class 0.000 description 2
- 102100021022 Gastrin Human genes 0.000 description 2
- 108010052343 Gastrins Proteins 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 description 2
- 208000000114 Pain Threshold Diseases 0.000 description 2
- 229920000148 Polycarbophil calcium Polymers 0.000 description 2
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 2
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000009858 acid secretion Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940069428 antacid Drugs 0.000 description 2
- 239000003159 antacid agent Substances 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 208000024330 bloating Diseases 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002169 ethanolamines Chemical class 0.000 description 2
- 150000002171 ethylene diamines Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000037040 pain threshold Effects 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 150000004885 piperazines Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000001562 ulcerogenic effect Effects 0.000 description 2
- QOPBEBWGSGFROG-UHFFFAOYSA-N 2-(1h-indol-2-yl)acetic acid Chemical class C1=CC=C2NC(CC(=O)O)=CC2=C1 QOPBEBWGSGFROG-UHFFFAOYSA-N 0.000 description 1
- PJJGZPJJTHBVMX-UHFFFAOYSA-N 5,7-Dihydroxyisoflavone Chemical compound C=1C(O)=CC(O)=C(C2=O)C=1OC=C2C1=CC=CC=C1 PJJGZPJJTHBVMX-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015137 Eructation Diseases 0.000 description 1
- 206010017865 Gastritis erosive Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000024659 Hemostatic disease Diseases 0.000 description 1
- 208000034991 Hiatal Hernia Diseases 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 206010067171 Regurgitation Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- 229940124623 antihistamine drug Drugs 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 208000027687 belching Diseases 0.000 description 1
- 229940092732 belladonna alkaloid Drugs 0.000 description 1
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 1
- 229960000782 bismuth subsalicylate Drugs 0.000 description 1
- ZREIPSZUJIFJNP-UHFFFAOYSA-K bismuth subsalicylate Chemical compound C1=CC=C2O[Bi](O)OC(=O)C2=C1 ZREIPSZUJIFJNP-UHFFFAOYSA-K 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229940095498 calcium polycarbophil Drugs 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- GUBNMFJOJGDCEL-UHFFFAOYSA-N dicyclomine hydrochloride Chemical compound [Cl-].C1CCCCC1C1(C(=O)OCC[NH+](CC)CC)CCCCC1 GUBNMFJOJGDCEL-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical group O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 229960004192 diphenoxylate Drugs 0.000 description 1
- SHTAFWKOISOCBI-UHFFFAOYSA-N diphenoxylate hydrochloride Chemical compound [Cl-].C1CC(C(=O)OCC)(C=2C=CC=CC=2)CC[NH+]1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 SHTAFWKOISOCBI-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000007911 effervescent powder Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960001571 loperamide Drugs 0.000 description 1
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001711 oxyntic cell Anatomy 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 238000011300 routine therapy Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 235000011182 sodium carbonates Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000009960 sympathetic pathway Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000004760 visceral afferent Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43083789A | 1989-11-02 | 1989-11-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69006684D1 DE69006684D1 (de) | 1994-03-24 |
| DE69006684T2 true DE69006684T2 (de) | 1994-06-09 |
Family
ID=23709269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69006684T Revoked DE69006684T2 (de) | 1989-11-02 | 1990-11-01 | Verwendung einer Zusammensetzung zur Herstellung eines Arzneimittels zur Behandlung der Symptome der Unenthaltsamkeit. |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0426479B1 (enExample) |
| JP (1) | JPH03206052A (enExample) |
| KR (1) | KR910009254A (enExample) |
| AT (1) | ATE101515T1 (enExample) |
| AU (1) | AU646230B2 (enExample) |
| CA (1) | CA2028746C (enExample) |
| DE (1) | DE69006684T2 (enExample) |
| ES (1) | ES2057439T3 (enExample) |
| GR (1) | GR1002097B (enExample) |
| IE (1) | IE64953B1 (enExample) |
| IN (1) | IN171746B (enExample) |
| NZ (1) | NZ235877A (enExample) |
| PT (1) | PT95753A (enExample) |
| ZA (1) | ZA908775B (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0550083T3 (da) * | 1991-12-06 | 1999-10-11 | Glaxo Group Ltd | Lægemidler til behandling af inflammatoriske tilstande eller til analgesi og indeholdende et NSAID og ranitidinbismuthcitra |
| CA2144155A1 (en) * | 1992-09-29 | 1994-04-14 | Robert T. Sims | Ibuprofen-h2 antagonist combinations |
| GB9221414D0 (en) * | 1992-10-13 | 1992-11-25 | Glaxo Group Ltd | Pharmaceutical compositions |
| US5648355A (en) * | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| SE9600072D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE9600070D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| ZA975444B (en) * | 1996-06-20 | 1998-12-21 | Mcneil Ppc Inc | Acetaminophen and meclizine hydrochloride analgesics |
| WO1998058637A1 (en) * | 1996-06-20 | 1998-12-30 | Mcneil-Ppc | Acetaminophen and diphenhydramine analgesics |
| DE19801811B4 (de) * | 1998-01-19 | 2004-12-23 | Stada Arzneimittel Ag | Pharmazeutische Zubereitung zur oralen Verabreichung |
| US7799766B2 (en) | 1998-04-08 | 2010-09-21 | Theta Biomedical Consulting & Development Co., Inc. | Composition for treating hormonally-dependent cancers |
| US7906153B2 (en) | 1998-04-08 | 2011-03-15 | Theta Biomedical Consulting & Development Co., Inc. | Anti-inflammatory compositions for treating multiple sclerosis |
| US20050220909A1 (en) | 2004-03-30 | 2005-10-06 | Theoharides Theoharis C | Composition for protection against superficial vasodilator flush syndrome |
| GB9911017D0 (en) * | 1999-05-13 | 1999-07-14 | Zeneca Ltd | Pharmaceutical compositions |
| IL145220A0 (en) * | 1999-05-20 | 2002-06-30 | Par Pharmaceutical Inc | Stabilized composition based on pyridinyl-sulfinyl-benzimidazoles and process |
| AU4973800A (en) * | 1999-06-09 | 2000-12-28 | Eli Lilly And Company | Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist |
| SE0000774D0 (sv) | 2000-03-08 | 2000-03-08 | Astrazeneca Ab | New formulation |
| CZ20032398A3 (cs) * | 2001-03-08 | 2004-02-18 | Astrazeneca Ab | Nové použití derivátů 6-karboxamidoimidazo [1,2-a] pyridinu |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| DK1411900T4 (da) | 2001-06-01 | 2014-01-27 | Pozen Inc | Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs |
| SE0102993D0 (sv) | 2001-09-07 | 2001-09-07 | Astrazeneca Ab | New self emulsifying drug delivery system |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20040185032A1 (en) * | 2003-03-18 | 2004-09-23 | David Burrell | Compositions and methods for treating colic |
| US7923043B2 (en) | 2004-03-30 | 2011-04-12 | Theta Biomedical Consulting & Development Co., Inc. | Method for protecting humans against superficial vasodilator flush syndrome |
| US7776873B2 (en) * | 2005-12-01 | 2010-08-17 | Yuhan Corporation | Method for treating damage to gastric mucosa |
| EP3090739A1 (en) * | 2008-01-04 | 2016-11-09 | Schabar Research Associates LLC | Compositions composed of naproxen sodium and nizatidine |
| KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
| MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
| US9176146B2 (en) | 2009-08-03 | 2015-11-03 | Theta Biomedical Consulting & Development Co., Inc. | Methods of treating autism spectrum disorders and compositions for same |
| US9050275B2 (en) | 2009-08-03 | 2015-06-09 | Theta Biomedical Consulting & Development Co., Inc. | Methods of screening for and treating autism spectrum disorders and compositions for same |
| US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| US11324727B2 (en) | 2020-07-15 | 2022-05-10 | Schabar Research Associates, Llc | Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn |
| JP2023534810A (ja) | 2020-07-15 | 2023-08-14 | シャバー リサーチ アソシエイツ エルエルシー | 急性痛の処置並びに胸やけの重症度及び／又はリスクの低減のための、イブプロフェン及びファモチジンから構成される単位経口用量組成物 |
| US12514846B2 (en) | 2020-07-15 | 2026-01-06 | Schabar Research Associates Llc | Unit oral dose compositions composed of ibuprofen or a pharmaceutically acceptable salt thereof and famotidine or a pharmaceutically acceptable salt thereof for the treatment of acute pain and the reduction of the severity and/or risk of heartburn and/or upset stomach |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2105193B (en) * | 1981-09-04 | 1984-09-12 | Glaxo Group Ltd | Pharmaceutical compositions containing non-steroidal anti-inflammatory agents |
| US4522826A (en) * | 1984-02-08 | 1985-06-11 | Richardson-Vicks Inc. | Analgesic and anti-inflammatory compositions comprising diphenhydramine and methods of using same |
| US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
-
1990
- 1990-10-29 IN IN907/CAL/90A patent/IN171746B/en unknown
- 1990-10-29 NZ NZ235877A patent/NZ235877A/xx unknown
- 1990-10-31 PT PT95753A patent/PT95753A/pt not_active Application Discontinuation
- 1990-10-31 AU AU65689/90A patent/AU646230B2/en not_active Ceased
- 1990-10-31 CA CA002028746A patent/CA2028746C/en not_active Expired - Lifetime
- 1990-11-01 EP EP90311995A patent/EP0426479B1/en not_active Revoked
- 1990-11-01 DE DE69006684T patent/DE69006684T2/de not_active Revoked
- 1990-11-01 ES ES90311995T patent/ES2057439T3/es not_active Expired - Lifetime
- 1990-11-01 AT AT90311995T patent/ATE101515T1/de not_active IP Right Cessation
- 1990-11-01 IE IE394690A patent/IE64953B1/en not_active IP Right Cessation
- 1990-11-01 ZA ZA908775A patent/ZA908775B/xx unknown
- 1990-11-01 KR KR1019900017661A patent/KR910009254A/ko not_active Ceased
- 1990-11-01 GR GR900100786A patent/GR1002097B/el not_active IP Right Cessation
- 1990-11-02 JP JP2298713A patent/JPH03206052A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IN171746B (enExample) | 1992-12-26 |
| ZA908775B (en) | 1992-07-29 |
| KR910009254A (ko) | 1991-06-28 |
| GR900100786A (el) | 1992-04-17 |
| EP0426479B1 (en) | 1994-02-16 |
| ATE101515T1 (de) | 1994-03-15 |
| AU6568990A (en) | 1991-05-09 |
| IE64953B1 (en) | 1995-09-20 |
| NZ235877A (en) | 1992-09-25 |
| CA2028746A1 (en) | 1991-05-03 |
| JPH03206052A (ja) | 1991-09-09 |
| IE903946A1 (en) | 1991-05-08 |
| AU646230B2 (en) | 1994-02-17 |
| PT95753A (pt) | 1991-09-30 |
| DE69006684D1 (de) | 1994-03-24 |
| CA2028746C (en) | 1995-12-26 |
| GR1002097B (en) | 1995-12-28 |
| EP0426479A1 (en) | 1991-05-08 |
| ES2057439T3 (es) | 1994-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0426479B1 (en) | Use of a composition for the manufacture of a medicament for curing the symptoms of overindulgence | |
| US5417980A (en) | Pharmaceutical compositions and methods for treating the symptoms of overindulgence | |
| AT390878B (de) | Verfahren zur herstellung einer pharmazeutischen zubereitung unter einsatz eines analgetischen und antiinflammatorischen nichtsteroiden wirkstoffes | |
| DE3852481T2 (de) | Pharmazeutische zusammensetzungen, enthaltend s(+)ibuprofen, das in der hauptsache frei von seinem r(-)antipoden ist. | |
| DE69836735T2 (de) | Behandlung von darmverstopfung | |
| DE69133348T3 (de) | Behandlung von nicht-entzündlichen darmerkrankungen | |
| DE2551280A1 (de) | L-dopa-zubereitung | |
| DE60132444T2 (de) | Behandlung von reizkolon-syndrom oder -krankheit | |
| AT401468B (de) | Pharmazeutische zusammensetzungen mit einem gehalt an ranitidinwismutcitrat | |
| DE3786893T2 (de) | Piperidinderivat zur Schmerzbehandlung. | |
| AT389226B (de) | Verfahren zur herstellung einer analgetischen und antiinflammatorischen pharmazeutischen zubereitung | |
| DE69917230T2 (de) | Kombinationspräparat, das selektive nmda nr2b-antagonisten und cox-2 inhibitoren enthält | |
| CH659946A5 (de) | Analgetische und antiinflammatorische, ibuprofen enthaltende pharmazeutische zubereitung. | |
| DE60132008T2 (de) | Cetylmyristat und cetylpalmitat zur behandlung von ekzemen und/oder psoriasis | |
| CH668184A5 (de) | Verwendung von acyloxyalkanoylcholinsalzen fuer die herstellung eines mittels zur besserung und therapie von neuropsychiatrischen symptomen, die die demenz begleiten. | |
| DE69817379T2 (de) | Pharmazeutische zubereitungen enthaltend ibuprofen und domperidon zur behandlung von migräne | |
| DE69431986T2 (de) | Verwendung von granisetron zur behandlung von postoperativer übelkeit und erbrechen | |
| DE2708520C2 (enExample) | ||
| DE3213091A1 (de) | Verwendung von femoxetin oder einem pharmazeutisch vertraeglichen salz davon zur steuerung und verminderung von appetit und gewicht | |
| EP1001756B1 (de) | Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe | |
| DD242749A5 (de) | Verbesserte entzuendungshemmende zusammensetzungen und verfahren | |
| DE4319438C1 (de) | Arzneimittel auf der Grundlage von Ketoprofen zur Bekämpfung von Schmerzen und/oder Entzündungen und/oder Fieber an Menschen und Tieren | |
| EP0624373B1 (de) | Festes bismut- und amoxycillinhaltiges Arzneipräparat und seine Verwendung | |
| DE3545201A1 (de) | Synergistische kombination von flupirtin und 4-acetamido-phenol | |
| DE2820900A1 (de) | Arzneimittel zur behandlung von gastritiden, gastroduodenitiden und gastroduodenaler ulcera |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8363 | Opposition against the patent | ||
| 8331 | Complete revocation |